Apple Inc vs Alcon AG — how do they compare? Apple Inc trades at $304.64 (market cap $4.45T), while Alcon AG trades at $72.42 (market cap $36.44B). The key difference: Apple Inc is far larger — about 122.1× Alcon AG's market cap, and Alcon AG pays the higher dividend (0.48%). Which is the better fit depends on your goals.
| AAPL | ALC | |
|---|---|---|
Market Cap | $4.45T | $36.44B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $90.12 |
52-Week Low | $224.90 | $62.02 |
Enterprise Value | $4.47T | $40.28B |
Dividend Yield | 0.35% | 0.48% |
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.
Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →